Abstract Search

ea0086op2.1 | Adrenal and Cardiovascular | SFEBES2022

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Goodchild Emily , Senanayake Russell , Wu Xilin , Bashari Waiel , Salsbury Jackie , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Gillett Dan , Boros Istvan , Aigbirhio Franklin , Sadhev Anju , Bird Nicholas , Hader Stefan , Warnes Victoria , Cruickshank Kennedy , Cheow Heok , Drake William , Gurnell Mark , Brown Morris

Introduction: Our MATCH study demonstrated 11-C ligand MTO was non-inferior to adrenal vein sampling in predicting surgical outcomes of adrenalectomy in patients with PA. The 20-min half-life of 11-C imposes logistic constraints. We investigated an 18-F ligand, CETO; its 2h half-life permits use in any facility with fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan capability.Objective: To compare the detection of aldosterone-producing ade...

0 shares

Endocrine Abstracts

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

BiosciAbstracts

Endocrine Abstracts

Novel radiolabeled ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) compared to [11C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

BiosciAbstracts

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)